# Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy

> **NCT02024932** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Spinal and Bulbar Muscular Atrophy

## Interventions

- **DRUG:** BVS857
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02024932
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-04
- **Primary completion:** 2016-04-13
- **Final completion:** 2016-04-13
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02024932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02024932, "Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02024932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*